Navigation Links
Pro Quarterback David Garrard Aims to Score Big For Crohn's Disease During the 2009 Football Season
Date:9/9/2009

HORSHAM, Pa., Sept. 9 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that the In the Zone for Crohn's program with David Garrard, quarterback for the Jacksonville Jaguars((R))(1) will continue this football season to raise awareness and provide funding for Crohn's disease research, education and support. Building on the success of last year's program, which raised $170,000 for the Crohn's & Colitis Foundation of America (CCFA), Centocor Ortho Biotech will again make a donation of $10,000 to the CCFA for each touchdown Garrard scores, passing or rushing, during the 2009 NFL season.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090909/PH72243 )

More information about the In the Zone for Crohn's program can be found at www.CrohnsintheZone.com, where visitors can track Garrard's progress throughout the season. Crohn's disease, combined with a related inflammatory bowel disease (IBD) called ulcerative colitis (UC), affects more than 1.4 million Americans.

"I feel fortunate to be able to bring even greater awareness to this often misunderstood condition," said David Garrard, quarterback of the Jacksonville Jaguars. "Through my play on the field and by speaking out on my condition, I hope to continue to further educate the public and be an example to others who are living with Crohn's disease."

The program will kick off with the Jaguars' first game of the season on September 13 and will culminate at the end of the 2009 season. A contribution will be donated to the CCFA based on Garrard's total touchdown performance. The In the Zone for Crohn's program kicked off during the 2008 season. By the end of the season, Garrard helped raise $170,000 for the CCFA through his play on the field.

"David's ongoing commitment to raising awareness of Crohn's disease is commendable and his story is inspirational," said Richard Geswell, President of the Crohn's & Colitis Foundation of America. "Through this continued partnership with Centocor Ortho Biotech Inc. on the In the Zone for Crohn's program, we look forward to enhancing a number of our educational and research programs to ultimately improve the lives of patients struggling with Crohn's disease and ulcerative colitis on a daily basis."

Despite Crohn's disease, Garrard continues to succeed on the field and has scored nearly 50 touchdowns over the past three seasons for the Jaguars. Garrard is entering his third season as their full-time starting quarterback.

(David Garrard is compensated for his participation in the "In the Zone for Crohn's" campaign, which is sponsored by Centocor Ortho Biotech.)

About David Garrard

David Garrard knows first hand the painful, debilitating and often embarrassing effects of Crohn's disease. Prior to the 2004 football season, Garrard began experiencing the excruciating symptoms associated with the disease, lost a significant amount of weight and missed several weeks of pre-season training. Following his diagnosis, David underwent surgery and, in consultation with his doctor, began a treatment regimen. David returned to the playing field by the start of the 2004 season and in 2007 led the team to its first playoff win in eight years.

About Crohn's Disease

Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract, affects approximately 500,000 Americans, including approximately 100,000 pediatric patients. The cause of Crohn's disease is not known, but the disease is associated with an abnormality of the immune system that could be triggered by viral or bacterial infections, a genetic predisposition or diet. Symptoms of Crohn's disease can vary but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss and fever. There is currently no cure for Crohn's disease.

About The Crohn's & Colitis Foundation of America (CCFA)

The Crohn's & Colitis Foundation of America's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with more than 80 cents of every dollar the Foundation spends goes to mission-critical programs. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau's Wise Giving Alliance (give.org) and the American Institute of Philanthropy (charitywatch.org). For more information, contact the Foundation at 800-932-2423 or visit www.ccfa.org.

About Centocor Ortho Biotech Inc.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology, and oncology. The company was formed when Centocor, Inc. and Ortho Biotech Inc. were consolidated in late 2008, and was renamed Centocor Ortho Biotech Inc. Built upon a pioneering history, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care.

(1) Jacksonville Jaguars is a registered trademark of the National Football League.


'/>"/>
SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Professional Quarterback Matt Leinart Teams Up With American Red Cross to Promote CPR/AED Awareness
2. Hall-of-Fame Quarterback, John Elway, Chooses Denver's Own Icon LASIK for Laser Vision Correction
3. NFL Quarterback Jay Cutler to Help Families Affected by Diabetes by Joining Lillys Inspired by Diabetes Campaign
4. Audi Teamed Up With Star Quarterback Tom Brady and Celebrities to Support People With Intellectual Disabilities
5. Hall of Fame Quarterback Takes Hit From Prostate Cancer, Urges Men to be Proactive About Their Own Prostate Health
6. WorldHeart Appoints David Pellone Chief Financial Officer
7. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
8. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
9. The Law Offices of John David Hart: Texas Man Sues Medtronic in Body-Snatching Case
10. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
11. St. Davids Medical Center Implements New Robotic Technology to Treat Common Heart Rhythm Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Kennett Square, PA (PRWEB) , ... March 23, 2017 , ... ... sunny days. That means many students are thinking about summer internships , which ... (or lack thereof). , The pros at Garden Media Group, a boutique public relations ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... products at competitive pricing. Verisys through its FACIS and other ... restrictions and Disciplinary actions. , “We are delighted to be able to offer ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... stands with all Americans facing life-altering and fatal diseases in opposition to the ... shortsighted decisions that would eviscerate care, services, and hope for the most vulnerable ...
(Date:3/23/2017)... ... March 23, 2017 , ... On ... Dagger Foundation the US Special Operations Command’s Patriot Award. The award was presented ... thanked Task Force Dagger Foundation for its significant and enduring support to the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The Boulevard ... 10am - 2pm. All events will be located in the Main West Entrance ... a no-cost Child ID event. No appointment is necessary and each child with a ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Md. , March 23, 2017  The U.S. ... Bavencio (avelumab) for the treatment of adults and pediatric ... carcinoma (MCC), including those who have not received prior ... MCC, a rare, aggressive form of skin cancer. ... common cancers, patients with a rare form called Merkel ...
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, ... ) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical ... diseases, today announced that data from its successful Phase ... a focal treatment for localized prostate cancer, will be ... the 32 nd Annual European Association of Urology ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... their offering. ... The global oxygen therapy devices market to grow at a CAGR ... Global Oxygen Therapy Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: